04:29 PM EDT, 07/11/2024 (MT Newswires) -- Nurix Therapeutics ( NRIX ) late Thursday reported a Q2 net loss of $0.71 per diluted share compared with a loss of $0.45 loss a year earlier.

Analysts polled by Capital IQ expected a loss of $0.63.

Total revenue for the quarter ended May 31 was $12.1 million, down from $30.7 million a year earlier.

Analysts expected $21.8 million.

The biopharmaceutical company finished the quarter with $452.5 million in cash and equivalents compared with $254.3 million at the end of February.

Price: 21.80, Change: -0.23, Percent Change: -1.04